New immune therapy shows promise for tough blood cancer

NCT ID NCT07374029

Recruiting now Disease control Sponsor: David Avigan Source: ClinicalTrials.gov ↗

First seen Jan 28, 2026 · Last updated May 22, 2026 · Updated 22 times

Summary

This early-phase study tests a new treatment for acute myeloid leukemia (AML) that combines a personalized immune cell therapy with standard chemotherapy drugs. The therapy uses the patient's own immune cells, trained to attack the cancer, along with a vaccine to boost the immune response. The main goals are to see if this combination is safe and can be made for each patient, with up to 30 adults taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA, IN RELAPSE